At Incyte, our research is grounded in the relentless pursuit of scientific excellence and the conviction that the advancement of basic science can drive the discovery of innovative medicines for patients. Our world-class researchers are focused on transforming the treatment of cancer and inflammatory and autoimmune conditions, and are advancing a diversified portfolio of clinical candidates.

OVERVIEW OF OUR PORTFOLIO

Molecular Targets
20

Clinical Candidates
23

Portfolio

Filter by:
Filters

Updated as of May 4, 2021

Please refer to local prescribing information for more information, including full safety information, on Incyte’s marketed medicines, or on medicines marketed by Incyte’s collaboration partners.
1. Jakafi marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis ex-U.S. 2. Approved in the U.S. 3. Approved in the U.S. and Japan 4. Development in collaboration with MorphoSys and co-commercialization in the U.S. with MorphoSys 5. European rights to Iclusig licensed from ARIAD 6. Approved in the European Union 7. Certain development programs conducted in collaboration with Novartis 8. In collaboration with MacroGenics 9. In collaboration with Merus 10. Licensed from Calithera 11. Discovery collaboration with Agenus 12. Worldwide rights to baricitinib licensed to Lilly 13. Approved in multiple territories globally 14. Worldwide rights to capmatinib licensed to Novartis 15. Approved in the US and Japan 16. Authorized in the U.S. for use under an Emergency Use Authorization (EUA), in combination with remdesivir, for treatment of certain hospitalized patients with suspected or laboratory confirmed COVID-19

Clinical Trials

We have numerous clinical trials underway across Oncology and Inflammation & Autoimmunity research areas. Incyte-sponsored studies can be found at www.IncyteClinicalTrials.com.

Incyte also supports significant independent research aimed at advancing the study of our products. A team of professionals scrutinizes all proposals submitted to Incyte for scientific merit and alignment with Incyte’s research goals. If you are interested in submitting a research proposal, please visit our online portal at iir.incyte.com.

Learn more about our target molecules currently in clinical development

For questions concerning Investigator Initiated Research conducted outside of the US, please contact Incyte at Global_IIR@incyte.com.

For questions concerning Investigator Initiated Research conducted in the US, please contact Incyte at US_IIR@incyte.com.